Successful Treatment of Relapsed/refractory Transformed Aggressive B-cell Lymphoma with Polatuzumab Vedotin Combined with Bendamustine and Rituximab Followed by Non-myeloablative Related HLA-haploidentical Stem Cell Transplantation
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Sarkozy C, Maurer M, Link B, Ghesquieres H, Nicolas E, Thompson C
. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol. 2018; 37(2):144-152.
PMC: 6366812.
DOI: 10.1200/JCO.18.00400.
View
2.
Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros L
. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol. 2003; 120(2):246-53.
DOI: 10.1309/R01V-XG46-MFCD-VNHL.
View
3.
Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J
. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2021; 112(7):2845-2854.
PMC: 8253277.
DOI: 10.1111/cas.14937.
View
4.
Gerhardt K, Jentzsch M, Georgi T, Sretenovic A, Cross M, Bach E
. Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. Front Oncol. 2021; 11:737645.
PMC: 8481921.
DOI: 10.3389/fonc.2021.737645.
View
5.
Sugita J, Kamimura T, Ishikawa T, Ota S, Eto T, Kuroha T
. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2020; 56(3):596-604.
DOI: 10.1038/s41409-020-01065-0.
View